Technology Offerings

Chimeric Nucleases: Precision Gene Targeting for Therapy

Chimeric nucleases known at present share the disadvantage that these enzymes cleave DNA in the genome also unspecifically, a feature resulting in unacceptable cytotoxicity. The new chimeric nucleases however exhibit an increased preference and specificity for DNA cleavage sites composed of two or three recognition sites and allow single cuts in the genome which reduces the toxic side effects substantially. Within the scope of gene targeting it is therefore now possible to introduce desired genes or genome segments into cleavage sites with high specificity.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

Comments (0)

Write a comment